AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 291 min read$CODX

CODX Q3'26 Earnings: revenue estimate is 169.00K USD

Co-Diagnostics (CODX) will report Q3'26 earnings on November 5. Analysts expect revenue of 169,000 USD and a loss of 1.25 USD per share. The announcement is scheduled for 7:00 AM ET.

Original reporting
tradingview.com
Published Oct 29, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 11:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
CODX Q3'26 Earnings: revenue estimate is 169.00K USD — source image
Source · tradingview.com
Decision brief

The 30-second read

$CODXNeutralLow
01

Why it matters

The preview provides the first public estimate for Q3'26, which may set expectations for the upcoming release.

02

Market read

The article offers a preliminary earnings estimate for a micro‑cap, likely of limited interest to broader markets.

03

What to watch

Potential hidden cash burn or upcoming regulatory milestones not mentioned in the preview.

Relevance 4/10Novelty 3/10Timing: pre‑market on Nov 5

Background

Co‑Diagnostics, Inc. (CODX) is a small diagnostics company that reports quarterly results.

Company-level read

Ticker impact

$CODXNeutralMedium confidence
Context

Company will release Q3'26 earnings on Nov 5 with revenue estimate of $169K and EPS of -$1.25.

Expected impact

likely slight pressure if results miss the modest estimate; limited upside if beat.

Evidence & confidence

Micro‑cap earnings with very small absolute numbers usually generate limited market reaction; the forecast is negative EPS, suggesting potential downside.

Market effects

Sector

Minimal impact on the diagnostics sector given the company's tiny scale.

Regional

Limited to investors tracking micro‑cap biotech stocks.

Global

None

Counterpoint

What could challenge this read

If the company surprises to the upside, the low estimate could be a buying opportunity.

Key entities

  • Company
    Co‑Diagnostics, Inc.

    Issuer of the earnings preview.

Read at source← All news

Related articles

OCT 27
$CODXMed

CoSara submits tuberculosis test for India regulatory review

Co-Diagnostics' India joint venture, CoSara, submitted its tuberculosis test for regulatory review in India, reporting 97.3% sensitivity and 96.0% specificity. The test, using Co-Diagnostics' technology, aims for approval by Q4 2026 to begin sales in India and South Asia. India has the highest tuberculosis burden globally, according to the WHO.

investing.com2 min
OCT 27
$CODXMedAI 8/10

Co-Diagnostics' Joint Venture CoSara Diagnostics Completes Clinical Study and Regulatory Submission for Point-of-Care Tuberculosis Test, Sets Stage for Commercial Launch in India

Co-Diagnostics' joint venture CoSara Diagnostics completed a clinical study for its tuberculosis test, reporting 97.3% sensitivity and 96.0% specificity. The test was submitted to India's CDSCO for regulatory clearance, with a commercial launch anticipated before year-end 2026. The company has also deployed mobile and cloud infrastructure in India to support the launch.

prnewswire.com2 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue was $0.17M vs $0.16M a year earlier. Operating loss was $6.2M, net loss $6.3M ($1.46/share). Cash was $3.6M. The company said it completed studies and submitted a 510(k) for its Flu A/B and RSV multiplex test, and raised $3.0M via private placement.

prnewswire.com6 min
AUG 13
$CODXMed

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. (CODX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion Strengthening Integrated Co-Dx PCR Platform Through Scientific Innovation, Cloud Connectivity and AI-

SEC EDGAR 8-K6 min
AUG 13
$CODXMed

Co-Diagnostics submits flu/RSV test after study of more than 1,400 patients

Co-Diagnostics (Nasdaq: CODX) reported Q2 2026 revenue of $0.17 million, up from $0.16 million a year earlier, with a net loss of $6.3 million ($1.46/share) versus a $7.7 million loss in Q2 2025. Cash fell to $3.6 million from $11.9 million. The company said it completed studies for an FDA 510(k) and CLIA waiver for its Flu A/B & RSV PCR test and raised $3.0 million in a private placement.

stocktitan.net6 min